Advertisement
Dr. Browne's presentation will take place at 12:45 p.m. local time onMonday, September 17 in the George D. Smith Room and will be immediatelyfollowed by a Q&A session. The presentation will include an overview of theCompany's drug development pipeline, including an update on its clinicalstudies with PS433540, recent corporate accomplishments and upcomingmilestones. A live webcast and 90-day archive of the presentation can beaccessed at http://www.pharmacopeia.com .
Advertisement
ABOUT PHARMACOPEIA
Pharmacopeia is committed to discovering and developing novel therapeuticsto address significant medical needs. The Company has a broad portfolioadvancing toward clinical validation, both independently and with partners.Pharmacopeia's most advanced internal program is a dual-acting angiotensin andendothelin receptor antagonist (DARA) for hypertension and diabetic kidneydisease for which Phase 1 clinical trials are underway. Other internalproprietary programs address primarily immunoregulation. Pharmacopeia'scollaborative efforts have resulted in a portfolio that includes one partneredprogram currently in Phase 2 clinical trials targeting chronic obstructivepulmonary disease (COPD) and three partnered programs in Phase 1 clinicaltrials targeting oncology and inflammatory diseases. Four additionalpartnered compounds are in preclinical development. Pharmacopeia's currentstrategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.
This press release, and oral statements made with respect to informationcontained in this press release, constitute forward-looking statements withinthe meaning of the Private Securities Litigation Reform Act of 1995. Suchforward-looking statements include those which express plan, anticipation,intent, goal, contingency or future development and/or otherwise are notstatements of historical fact. These statements are based upon management'scurrent expectations and are subject to risks and uncertainties, known andunknown, which could cause actual results and developments to differmaterially from those expressed or implied in such statements. These forward-looking statements include, but are not limited to, statements about thesuccessful implementation of Pharmacopeia's strategic plans, Pharmacopeia'splans to develop PS433540, a product candidate from its DARA program,Pharmacopeia's Phase 1 clinical studies and proposed Phase 2 clinical studieswith respect to PS433540, including timing and expected outcomes of suchstudies, Pharmacopeia's estimates of the market opportunities for its productcandidates, including PS433540, Pharmacopeia's ability to successfully performunder its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth,Pharmacopeia's ability to build its pipeline of novel drug candidates throughits own internally-funded drug discovery programs, third party collaborationsand in-licensing, Pharmacopeia's ability to raise additional capital,Pharmacopeia's expectations concerning the development priorities of itscollaborators, their ability to successfully develop compounds and its receiptof milestones and royalties from the collaborations, Pharmacopeia'santicipated operating results, financial condition, liquidity and capitalresources, Pharmacopeia's expectations concerning the legal protectionsafforded by U.S. and international patent law, Pharmacopeia's ability topursue the development of new compounds and other business matters withoutinfringing the patent rights o
